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Isolated hepatitis B core antibody in HIV infected 
patients--can response to hepatitis B vaccine 
help to elucidate the cause? 
 
Abstract 
Background: Concomitant hepatitis B and HIV infections are common. In some of these 
patients, HBcAb is the only serologic marker of hepatitis B. This study was conducted to 
elucidate the cause of isolated HBcAb in HIV-infected patients via hepatitis B vaccination. 
Methods: In this interventional study during 2014-15 in the HIV Clinic in Hamadan, thirty 
four patients with HIV infection and isolated HBcAb positive isolate, received hepatitis B 
vaccine and their responses to vaccination were investigated. Demographic data, stage of 
disease, and status of CD4 and HCV Ab were extracted from the patients' medical records 
and were entered in a checklist. 
Results: Of the 103 HIV positive patients, the prevalence of HBs Ag, and HBc Ab isolates 
were 6.79% (n=7) and 46.6% (n=48), respectively. All of the patients with isolated HBcAb 
were positive for HCV Ab. Among the 48 patients with isolated HBc Ab, 34 (70.8%) were 
available and examined for HBV DNA in serum samples. The result of PCR was negative 
in all. After the first round of hepatitis B vaccination, HBs Ab titer exceeded 10 
International Units Per Liter (IU/L) in 58.8% of patients with isolated HBc Ab. With the 
completion of the three-dose of vaccine, this titer was observed in 97% of patients. 
Significant correlation was observed between titer of antibodies and values of CD4 cells. 
Conclusions: Due to favorable response to hepatitis B vaccination in HIV positive patients 
with isolated HBc Ab, false positive HBc Ab and recovery from previous infection were 
more probable than hidden hepatitis B. 
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With the increasing rate of HIV prevalence across many countries; this disease is 
considered globally pandemic. According to reports of the joint United Nations program 
on HIV/AIDS (UNAIDS), it is estimated that 35 million people worldwide were living 
with HIV virus by the end of 2013, of whom, about 95% live in the developing countries 
(1).
 
Meanwhile, prevention, diagnosis and treatment of hepatitis B in patients with AIDS 
are particularly important. Recent studies have shown that the risk of mortality in patients 
with concomitant hepatitis B and AIDS infection is significantly higher than in patients 
with hepatitis B alone (2). All HIV patients should also be examined for hepatitis B 
infection. The evidence of active hepatitis B infection in AIDS patients exposes them to 
risk of cirrhosis, advanced liver diseases, and hepatocellular carcinoma. Treatment of 
hepatitis B in AIDS patients can be mainly aimed at preventing development of advanced 
liver diseases (2). A study showed that almost 80% of intravenous drug users with AIDS 
had serological markers of hepatitis B infection (3). 
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The presence of HBc Ab isolate in patients with AIDS 
indicates a hepatitis B serological change. HBc Ab isolate 
refers to the presence of antibody anti-core virus antigen in 
the absence of HBs Ab and HBs Ag (4). Some causes were 
suggested for isolated HBc Ab; first, isolated HBc Ab is seen 
in patients with chronic hepatitis B infection that its antigen 
level was too low to detect with serological examinations 
and both of HBs Ag and HBs Ab were negative (occult 
hepatitis B). Second, isolated HBc Ab was observed in 
patients who had recovered from hepatitis B or had prior 
vaccination but their HBs Ab level was too low for detection 
(5, 6)
 
and third, it should be false positive due to the present 
cross-reacting antibodies in HIV, HCV or co-infection of 
them (7, 8).
 
In patients whose HBs Ab level was too low to 
detect despite recovery from hepatitis B or prior vaccination, 
naturally, the antibody increased to higher than 10 IU/L after 
solitary vaccine dosage (9).  
In Chakvetadze et al.’ study on HIV patients with anti-
HBc and CD4 count above 200, they reported that one 
month after hepatitis B vaccination, 22% of participants 
showed anti-HBs titer above 10 IU/L, and the rest were 
identified as primary responders. After the course of three 
vaccinations, about 60% of primary responders showed anti-
HBs titer above 10 IU/L (10). There are still reports of 
unidentified issues in relation to the response rate of hepatitis 
vaccination in HIV patients. Accordingly, the present study 
aimed to investigate the different causes of isolated HBc Ab 
in HIV-infected patients by measurement of immune 
response to hepatitis B vaccination in the HIV clinic in 
Hamedan during 2015. 
 
 
Methods 
The present interventional study was conducted on HIV- 
infected patients in the HIV clinic in Hamadan during 2014-
2015. The study protocol was approved by the Ethics 
Committee of Hamadan University of Medical Sciences. 
First, the study participants underwent screening tests for 
hepatitis B. HBs Ag test was performed with a fourth 
generation ultra-version enzyme-linked immunoassay 
(ELISA) kit of DIA.PRO (Milano, Italy) using 
sample/control cutoff method (<0.9: negative, 0.9-1.1: 
equvocal, >1.1: positive). HBc Ab test was done with 
competitive enzyme immunoassay (ELISA) kit of DIA.PRO 
(Milano, Italy) using sample/control cutoff method (<0.9: 
negative, 0.9-1.1: equvocal, >1.1: positive). HBs Ab was 
measured using ELISA-kit of DIA.PRO (Milano, Italy) for 
quantitative determination of serum antibody level and the 
samples with a concentration higher than 10 mIU/ml 
considered as positive. CD4
+ 
lymphocytes count was 
detected by CyFlow Counter Sysmex Partec (Germany) 
device with flow cytometric and green laser excitation 
method using CD4/CD 4% easy count kit Sysmex reagents.  
Isolated HBcAb was defined as positive HBc Ab with 
negative HBs Ab and HBs Ag. Patients with isolated HBc 
Ab received HBV vaccination free of charge on three 
occasions: beginning of the study, one month and six months 
after the first vaccination. HBs Ab titer was measured three 
weeks after the first vaccination. In patients whose antibody 
titers increased higher than 10 IU/L after the first dose of 
hepatitis B vaccination, other doses of vaccine were not 
given. In patients whose antibody titer had not risen, second 
and third doses of HBV vaccine were injected and serum 
HBs Ab level was measured again three weeks after the third 
vaccination. A checklist was designed by researchers 
containing the date of referral, demographic details (age, 
gender), duration of infection, stage of disease, and status of 
CD4 and HCV Ab, which were extracted from the patients' 
records in HIV clinic and recorded in the checklist.  
Collected data were analyzed using SPSS-22. 
Quantitative data were described using mean and standard 
deviation while in qualitative data, frequency and percentage 
were used. For comparison of qualitative findings, we used 
chi-square test and McNemar’s test. With respect to 
quantitative findings, for antibody titer comparisons between 
the first and third vaccinations, we used Wilcoxon signed 
rank test; for antibody titer comparisons of HIV patients who 
did and did not receive antiretroviral treatment, we used 
Mann-Whitney U test as the antibody titer distribution did 
not turn out to be normal after checking for normality. We 
used Spearman correlation test to clarly the for relationship 
between antibody titer and the length of treatment, as well as 
CD4 and antibody titer after the first and third vaccinations. 
The significance level used in all tests was 5%. 
 
 
Results 
In the present study of 103 HIV positive patients, 101 
(98.1%) patients were men and two (1.9%) were women, 
with mean age 40.5±7.6 years. Participating patients were 
mostly in the 35-44 years age group (47.1%), where the 55-
64 years age group contained the fewest patients (1%); the 
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disease was not observed in the age group younger than 25 
years old. All of 103 HIV patients in the HIV clinic were 
screened for hepatitis B. Of the 103 HIV infected patients, 
seven (6.79%) were HBs Ag and HBc Ab positive, in 44 
(42.7%) patients HBs Ag and HBc Ab were negative, and 
finally 52 (50.5%) patients were HBs Ag negative and HBc 
Ab positive. The entire last group (i.e., negative HBs Ag and 
positive HBc Ab) had serologic evidence of hepatitis C 
infection and also history of hepatitis B vaccination before 
any complete screening for hepatitis B infection, where the 
mean time elapsed since vaccination was 6.26 years (1-10 
years). Of the 52 patients in this group, only 4 (7.7%) were 
positive for HBs Ab and 48 (92.3%) were negative. Among 
the 48 patients that had serologic evidence of isolated HBc 
Ab, 34 (70.8%) were available and examined for HBV 
DNA; results of PCR procedure of serum samples of these 
34 patients were negative (figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Flowchart of response to hepatitis B virus vaccine 
(HBV vaccine) in HIV positive patients with isolated hepatitis B 
core antibody (HBc Ab).  HBs Ag = Hepatitis B surface 
Antigen, HBs Ab = antibody to hepatitis B surface antigen 
With respect to the stage of HIV infection in these 
patients, 12 (35.3%) were in the first stage, 4 (11.8%) in the 
second, 12 (35.3%) in the third, and 2 (5.9%) in the fourth. 
The stage of the disease was unclear in 4 (11.8%) patients. 
Mean CD4 in patients with positive HIV and positive HBc 
Ab isolate was 337.12±203.4 (27-780). 
HBs Ab titer was greater than 10 in (20 of 34) 58.82% of 
patients after the first vaccination. In those patients whose 
antibody titer did not increase after the first dose of vaccine, 
positive titer of HBs Ab was found in (13 of 14) 92.86% 
after the third vaccination round (p< 0.05) (table 1).  
 
Table 1. HBs Ab titer of patients with positive HBc Ab 
isolate after the first and the third hepatitis B vaccination 
 
HBs Ab titer after the first and 
the third hepatitis B vaccination 
Value Count % 
HBs Ab 1 <10 14 41.18 
≥10 20 58.82 
Total  34 100 
HBs Ab 3 <10 1 7.14 
≥10 13 92.86 
Total  14 100 
 
Altogether, following vaccination HBs Ab titer in 33 
(97%) patients reached above 10 IU/L, and remained 
negative in one patient (3%) after all three rounds of 
vaccination. For the noted patient, polymerase chain reaction 
for hepatitis B was repeated and was negative in serum but 
PCR of the whole blood sample was positive for hepatitis B 
infection (figure 1).  
The Spearman correlation test showed no significant 
correlation between HBs Ab titer in the first (r=-14, P=0.34) 
and the third (r=14, P=0.34) vaccinations and the duration of 
receiving treatment for AIDS. The mean and standard 
deviation of hepatitis B antibody titer was 90.95±141.05 
after the first vaccination and 53.93±47.7 after the third. No 
significant difference was found between patients receiving 
and not receiving medication for AIDS in HBs Ab titer after 
the first or the third vaccination. 
In this study, no significant difference was observed 
between CD4 (below or above 200) and antibody titer 
(below or above 10).  
The Spearman correlation test showed a significant 
correlation between CD4 and HBs Ab titers after the first 
and the third vaccination (p<0.05) (table 2). 
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Table 2. Distribution of CD4 and HBs Ab titer in patients 
with positive HBc Ab isolate after the first and third 
hepatitis B vaccination 
 
Vaccination 
round 
Antibody 
titer 
CD4 Tot
al 
Pvalue 
< 200 > 200 
First < 10 5 9 14 0.28
*
 
≥ 10 5 15 20 
Total 10 24 34 
Third < 10 0 1 1 0.09
**
 
≥10 5 8 13 
Total 5 9 14 
*Chi-square test            ** Fisher's exact test 
 
Discussion 
The prevalence of isolated HBc Ab was 46.6% in this 
study, which is higher than values reported in other similar 
studies by Neau (17%) and Landrum (14%) (11, 12).
 
 It is 
estimated that isolated HBc Ab had been found in 10-20% of 
general population (13). Vaezjalali et al. reported that the 
prevalence of HBc Ab among healthy blood donors was 8% 
(14). In a study about patients with non-Hodgkin's 
lymphoma, Masarone reported that the prevalence of isolated 
HBc Ab positive was 26.9% (15); Sowole et al. reported that 
the prevalence of HBc Ab among dialysis patients was 20% 
(16). The prevalence of isolated HBc Ab among patients 
with HIV infection ranged from 17–81%, depending on the 
prevalence of HBV infection (8, 11, 17).
 
Higher prevalence 
of isolated HBc Ab was seen in HCV carriers and IV drug 
users (3, 18). In the present study, all 34 patients with 
isolated HBc Ab were IV drug users and HCV carriers. 
In different studies, higher prevalence of isolated HBc 
Ab in patients with HIV and HCV co-infection has been 
reported (8, 19-21). Some studies cite higher spread of occult 
hepatitis B infection (OBI) as the main reason for this 
observation (20, 21). They state that in case of concurrent 
HBV and HCV infection, replication of these viruses, and 
especially hepatitis B virus, are reduced that can cause OBI 
(21). On the other hand, some studies suggest the probability 
of false positive result and the cross effect of hepatitis C 
antibodies as the reason for higher spread of isolated HBc 
Ab in patients with HIV and HCV co-infection (8).
 
The 
general findings of our study are more consistent with the 
latter hypothesis.  
In the present study, in HIV positive patients with 
positive HBc Ab isolate, 35.3% were in the first stage of the 
disease, 11.8% and 35.3% were in the second and third 
stages, respectively and 5.9% in the fourth stage. In 11.8% of 
patients, stage of disease was not mentioned in their records. 
In this study, mean CD4 count was found to be 
337.12±203.4 cell/µL, which was less than that reported by 
Chakvetadze et al. (443 cell/µL), and that reported by 
Ramazani et al. (467.54±218.93 cell/µL) (10, 22). In a 
similar study, Jahanbakhsh et al. reported CD4 count of 
more than 500 cell/µL in 41.4% of patients, between 200 and 
449 cell/µL in 52.1%, and less than 200 cell/µL in 6.5% 
(23). It seems that HIV infected patients in our region were 
found to be in the late stage; therefore, we need to improve 
screening system to detect HIV infected patients in the early 
phases of the disease.  
In the present study, hepatitis B antibody titer was greater 
than 10 in 58.82% of patients after the first vaccination; 
among the remaining, positive titer of HBsAb seen in 
92.86% after the third vaccination round. Overall, following 
vaccination, HBsAb titer in 97% of patients reached above 
10 IU/L, and remained negative in 3% of them after all three 
vaccinations. The increase in antibody titer was greater than 
that reported in studies by Masako Mizusawa (42%) (24) and 
Chakvetadze (60%) (10).  
The difference may be attributed to patient immunity to 
hepatitis B in the present study as all patients had history of 
hepatitis B vaccination. In contrast to the present study, in 
Jahanbakhsh et al.’s study, a significant correlation was 
found between immunity response to hepatitis B vaccination 
and CD4 count, so the patients with CD4 count greater than 
500 showed better immunity response after hepatitis B 
vaccination (23). Similarly, in Mizusawa et al.’s study, a 
significant correlation was found between immunity 
response to hepatitis B vaccination and CD4 count at first 
vaccination (24). In Mizusawa’s study showed a rapid drop 
in HBs Ab in HIV positive patients 180 days after the third 
hepatitis B vaccination (24).  
In the present study, the mean of time-lapse since 
vaccination of the patients was 6.26 years.  According to our 
results, HBs Ab titer after HB vaccination or recovery of 
previous infection may be dropped over time and then 
increased due to immune stimulation after revaccination. On 
the other hand, in occult hepatitis B, we do not expect an 
increase in HBs Ab titer in response to revaccination, hence, 
occult hepatitis B is improbable. One patient in our study did 
not have increase in his antibody titer after three hepatitis B 
vaccinations. Although the primary and secondary PCR 
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study of his serum sample was negative for hepatitis B, PCR 
study of his whole blood sample was positive.  
In conclusion Given the satisfactory response of HIV 
positive patients with isolated HBc Ab to hepatitis B 
vaccination, false positive HBc Ab and recovery from 
previous infection were most probable than hidden hepatitis 
B. There is a need for further studies with more cases and 
compare isolated HBc Ab cases in HIV positive patients 
with and without hepatitis C infection for more 
comprehensive conclusions. 
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